David Vizarraga

This paper identifies a covalent irreversible inhibitor, Z34, that binds to ALDH1A3 in two distinct conformations at the active-site cysteine, showing promise for anticancer drug development.

The paper evaluates AI and first-principle methods for protein redesign, showing hybrid approaches are most reliable, while inverse folding tools and force fields have specific strengths and limitations.

This paper introduces EvolveX, a computational pipeline for designing stable single-domain antibodies with high affinity, demonstrating improved binding affinity to human targets.

The paper reports the cryo-EM structure of a bacterial adhesin complex and identifies epitopes that affect adhesion and motility in Mycoplasma pneumoniae.